Article

Visus Therapeutics launches phase 2 clinical trial for presbyopia treatment

Clinical-stage pharma company announces next step in investigation of BRIMOCHOL to treat presbyopia.


Visus Therapeutics announced today the beginning of its phase 2 clinical trial of BRIMOCHOLTMophthalmic solution currently under investigation for the treatment of presbyopia.

BRIMOCOHOL is a proprietary pupil-modulating eye drop consisting of two pharmaceuticals: carbachol (a cholinergic agent) and brimonidine tartrate (an alpha-2 agonist). A “pinhole effect,” is created by the combination, which sharpens distant and near images while minimizing any side effects. This results in vision clarity for near tasks such as reading or operating a smartphone.

The phase 2 clinical trial consists of a double-masked, randomized crossover study that evaluates the safety and efficacy of two proprietary formulations of BRIMOCHOL in patients with emmetropic phakic and pseudophakic presbyopia, according to a company news release.

Approximately 42 patients are expected to be enrolled, with the primary endpoint targeting the percentage of patients who gain three lines or more in near visual acuity without a loss of distance vision.

Top line data from the trial is expected in mid-2021, the release stated.

 

Related Videos
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
Image credit: Ophthalmology Times; EnVision Summit 2025: Sonia H. Yoo, MD, shares what to expect from the cataract and refractive agenda
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
© 2025 MJH Life Sciences

All rights reserved.